MNG503
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.320
- UNFOLDED_PROTEIN_RESPONSE+0.259
- MYC_TARGETS_V2+0.229
- PROTEIN_SECRETION+0.200
- MYC_TARGETS_V1+0.174
- HEDGEHOG_SIGNALING+0.150
- ESTROGEN_RESPONSE_EARLY+0.126
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.106
- GLYCOLYSIS+0.105
- UV_RESPONSE_DN+0.105
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.413
- TNFA_SIGNALING_VIA_NFKB-0.372
- ALLOGRAFT_REJECTION-0.367
- INFLAMMATORY_RESPONSE-0.350
- INTERFERON_GAMMA_RESPONSE-0.325
- E2F_TARGETS-0.281
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.279
- KRAS_SIGNALING_UP-0.272
- PEROXISOME-0.241
- G2M_CHECKPOINT-0.227
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG324 | — | — | 0.773 |
| 2 | 84ca3236-683a-40f6-b8a6-600ffd43a0da | — | — | 0.771 |
| 3 | TCGA-E9-A1R5-01A-11R-A14M-07 | — | B | 0.759 |
| 4 | TCGA-UF-A7JK-01A-11R-A34R-07 | — | — | 0.753 |
| 5 | MBCProject_0063_T1_RNA | — | C | 0.747 |
| 6 | MBCProject_6246_T1_RNA | — | C | 0.744 |
| 7 | R274 | — | — | 0.731 |
| 8 | TCGA-A7-A0D9-01A-31R-A056-07 | — | B | 0.712 |
| 9 | SRR25617868 | — | B | 0.691 |
| 10 | MBCProject_0343_T1_RNA | — | B | 0.688 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.259 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.229 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.174 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.126 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.106 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.105 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.105 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.083 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.040 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.022 | Inavolisib | — uncovered |
| COAGULATION | 0.011 | Binimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.003 | Remibrutinib | — uncovered |